<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165230</url>
  </required_header>
  <id_info>
    <org_study_id>02-011</org_study_id>
    <nct_id>NCT00165230</nct_id>
  </id_info>
  <brief_title>Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors</brief_title>
  <official_title>A Phase II Study of Thalidomide in Combination With Temodar in Patients With Metastatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good or bad, that thalidomide and&#xD;
      temodar have on patients with neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will receive thalidomide orally once daily continuously unless they experience&#xD;
           significant side effects. Temodar is given orally once a day for one week, followed by a&#xD;
           one week break period. This one week on/one week off schedule will continue for the&#xD;
           duration of treatment unless there are significant side effects.&#xD;
&#xD;
        -  After eight weeks (2 cycles) a CT scan will be performed to see how the treatment has&#xD;
           affected the patient's tumor. Patients will continue taking the study drug unless there&#xD;
           is evidence of tumor growth.&#xD;
&#xD;
        -  Regular blood tests will be done weekly during the first two months to make sure that&#xD;
           the treatment is not resulting in serious side effects. If there are no side effects&#xD;
           during the first two months, the blood tests may decrease in frequency to every two&#xD;
           weeks.&#xD;
&#xD;
        -  Immediately after the patient has completed the study they will be evaluated by physical&#xD;
           exam, blood work, and a CT scan. The follow-up will consist of clinic visits and phone&#xD;
           calls every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the response rate in patients with locally unresectable neuroendocrine tumors treated with temodar and thalidomide.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate overall response and progression free survival of this patient population</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to evaluate the safety of temodar and thalidomide.</measure>
  </secondary_outcome>
  <enrollment>32</enrollment>
  <condition>Neuroendocrine Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temodar</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed locally unresectable or metastatic neuroendocrine tumor&#xD;
             excluding small cell carcinoma&#xD;
&#xD;
          -  Prior treatment with chemoembolization or cryotherapy is allowed&#xD;
&#xD;
          -  Radiotherapy is allowed if completed more than 4 weeks prior to study.&#xD;
&#xD;
          -  Measurable disease as defined by RECIST criteria&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  ECOG performance status of less than or equal to 2&#xD;
&#xD;
          -  ANC &gt;1,500/mm3&#xD;
&#xD;
          -  Platelet Count &gt; 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dl&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &lt; 2 x ULN&#xD;
&#xD;
          -  SGOT and SGPT &lt; 2 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 x ULN&#xD;
&#xD;
          -  Life expectancy of greater than 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically symptomatic central nervous system metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Myocardial infarction in past 6 months&#xD;
&#xD;
          -  Major surgery in past two weeks&#xD;
&#xD;
          -  Uncontrolled serious medical or psychiatric illness&#xD;
&#xD;
          -  Insufficient recovery from all active toxicities of prior therapies&#xD;
&#xD;
          -  Active nonmalignant systemic disease&#xD;
&#xD;
          -  Frequent vomiting or medical condition that could interfere with oral medication&#xD;
             intake&#xD;
&#xD;
          -  Known HIV positivity or AIDS-related illness&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew H. Kulke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <keyword>thalidomide</keyword>
  <keyword>temodar</keyword>
  <keyword>metastatic neuroendocrine tumor</keyword>
  <keyword>unresectable neuroendocrine tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

